Odyssey Therapeutics, Inc. (ODTX)
Odyssey Therapeutics will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Company Description
Odyssey is a clinical-stage biopharmaceutical company led by a team and board of drug hunters seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases.
To accomplish this, we are developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system.
Our most advanced programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, for which we intend to commence a Phase 2a monotherapy trial for ulcerative colitis in the first quarter of 2025 and a Phase 2a combination trial with vedolizumab in the first half of 2026.
Odyssey Therapeutics, Inc.
| Country | United States |
| Founded | 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 151 |
| CEO | Gary D. Glick, Ph.D. |
Contact Details
Address: 51 Sleeper Street Boston, MA 02210 United States | |
| Phone | (617) 865-9628 |
| Website | odysseytx.com |
Stock Details
| Ticker Symbol | ODTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001882782 |
Key Executives
| Name | Position |
|---|---|
| Gary D. Glick, Ph.D. | President, Chief Executive Officer and Director |
| Julie Clauss | Chief Operating Officer |
| Jason Haas | Chief Financial Officer |
| William Roush, Ph.D. | Executive Vice President, Head of Small Molecule Research |
| Kira M. Schwartz | Executive Vice President, General Counsel and Secretary |
| Stephen Soisson, Ph.D. | Executive Vice President, Protein Therapeutics and Structural Biology |
| Collin Todd | Senior Vice President, Strategy and Business Development |
| Jeffrey M. Leiden, M.D., Ph.D. | Chair and Director |
| Charles Baum, M.D., Ph.D. | Director |
| Jill Carroll | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 17, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Dec 5, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Nov 18, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Oct 7, 2024 | DRS | [Cover] Draft Registration Statement |
| Aug 14, 2024 | D/A | Filing |
| Dec 15, 2023 | D | Notice of Exempt Offering of Securities |
| Oct 27, 2022 | D | Notice of Exempt Offering of Securities |
| Oct 14, 2021 | D | Notice of Exempt Offering of Securities |